


Improved Wound Healing: The Healing Power of Blood Transfusions for Individuals with HIV

*Emmanuel Ifeanyi Obeagu 

Department of Medical Laboratory Science, Kampala International University, Uganda

Article Info:

Article History:

Received 07 June 2024
Reviewed 20 July 2024
Accepted 19 August 2024
Published 15 September 2024

Cite this article as:

Obeagu EI, Improved Wound Healing: The Healing Power of Blood Transfusions for Individuals with HIV, International Journal of Medical Sciences & Pharma Research, 2024; 10(3):16-22

DOI: <http://dx.doi.org/10.22270/ijmspr.v10i3.107>

*Address for Correspondence:

Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda

Abstract

Wound healing in individuals with HIV is often compromised due to impaired immune function, chronic inflammation, and common comorbidities like anemia. Blood transfusions, traditionally used to manage anemia, have shown promise in enhancing wound healing through multiple mechanisms. This review explores the role of blood transfusions in improving wound healing for HIV-positive patients, focusing on their impact on oxygen delivery, immune modulation, inflammation reduction, and tissue repair. By restoring adequate hemoglobin levels, blood transfusions can improve oxygenation, support cellular metabolism, and promote collagen synthesis and angiogenesis, all crucial for effective wound healing. In addition to addressing anemia, blood transfusions may offer broader benefits, including the modulation of immune responses and the reduction of systemic inflammation. These effects can create a more favorable environment for wound healing, helping to mitigate prolonged inflammation and tissue damage commonly seen in HIV-positive individuals. Clinical studies and case reports have highlighted significant improvements in wound healing outcomes following transfusion therapy, underscoring its potential as a complementary intervention in HIV care.

Keywords: anemia, blood transfusions, HIV, immune response, wound healing.

Introduction

Wound healing is a multifaceted process essential for maintaining the integrity of the skin and underlying tissues following injury. This process involves a series of well-coordinated phases, including hemostasis, inflammation, proliferation, and remodeling, each requiring a precise interplay of cellular and molecular mechanisms. For individuals living with HIV, wound healing is often impaired due to a variety of factors, including compromised immune function, chronic inflammation, and prevalent comorbid conditions such as anemia. These challenges necessitate the exploration of adjunctive therapies that can support and enhance the natural wound healing process.¹ The advent of effective antiretroviral therapy (ART) has dramatically improved the life expectancy and quality of life for people living with HIV. However, despite these advancements, the management of comorbidities remains a significant aspect of HIV care. Anemia, in particular, is a common complication in HIV-infected individuals, often resulting from chronic disease, ART side effects, or opportunistic infections. Anemia exacerbates the already compromised wound healing capacity in these patients by reducing the oxygen-carrying capacity of the blood, thereby impairing cellular functions essential for tissue repair.² Blood

transfusions, a primary intervention for managing severe anemia, have been traditionally utilized to restore hemoglobin levels and improve oxygen delivery to tissues. Recent research suggests that blood transfusions may also play a crucial role in enhancing wound healing in HIV-positive patients. By addressing anemia, blood transfusions can improve cellular metabolism, support collagen synthesis, and promote angiogenesis, all of which are vital for effective wound healing. This potential extends beyond mere oxygenation, encompassing broader impacts on immune modulation and inflammation reduction.³

Wound healing involves an initial inflammatory response to clear debris and prevent infection, followed by the proliferation of new tissue and the formation of new blood vessels, culminating in the remodeling phase where the tissue regains its strength and functionality. Each phase is critically dependent on adequate oxygen supply, immune competence, and controlled inflammatory responses, all of which can be compromised in the context of HIV infection.⁴ In the hemostasis phase, blood clotting prevents excessive blood loss and provides a matrix for incoming cells. In HIV-positive individuals, platelet function and coagulation can be impaired, complicating this initial

step. Blood transfusions can enhance this phase by providing platelets and clotting factors, thus stabilizing the wound site and preparing it for subsequent healing stages. During the inflammation phase, immune cells such as neutrophils and macrophages are recruited to the wound site to clear pathogens and debris. However, in HIV-infected patients, immune cell function is often compromised, leading to prolonged and inefficient inflammation.⁵ The proliferation phase is marked by the migration and proliferation of fibroblasts, keratinocytes, and endothelial cells, which form new tissue and blood vessels. Oxygen is a critical factor during this phase, as it supports cellular metabolism and ATP production necessary for cell division and migration. Anemia, common in HIV patients, impairs this oxygen delivery, slowing down the healing process. Blood transfusions can correct anemia, thereby enhancing oxygenation and supporting cellular activities crucial for tissue formation.⁶ In addition to improving oxygen delivery, blood transfusions may exert beneficial effects on immune function. HIV infection is associated with chronic immune activation and systemic inflammation, which can impede the wound healing process. Blood transfusions can modulate immune responses by replenishing immune cells and reducing inflammatory mediators, creating a more conducive environment for tissue repair. This immune modulation is particularly important for HIV-positive individuals, whose immune systems are often dysregulated due to ongoing viral replication and the effects of ART.⁷

Chronic inflammation is another significant barrier to effective wound healing in HIV-positive patients. Persistent inflammation can lead to excessive tissue damage and scarring, prolonging the healing process and increasing the risk of chronic wounds. Blood transfusions have been shown to reduce levels of pro-inflammatory cytokines and other inflammatory markers, thereby mitigating chronic inflammation and promoting a more balanced healing response. This reduction in systemic inflammation can facilitate the transition from the inflammatory phase to the proliferation phase, enabling more efficient tissue repair.⁸ Clinical evidence supporting the role of blood transfusions in enhancing wound healing in HIV-positive individuals is growing. Studies have demonstrated that patients receiving blood transfusions for severe anemia show significant improvements in wound healing outcomes, including faster wound closure and improved tissue quality. These findings suggest that blood transfusions, by addressing anemia and modulating immune responses, can significantly enhance the natural wound healing process in this vulnerable population.⁹⁻¹⁰ Despite the promising potential of blood transfusions, their use in HIV-positive patients must be approached with caution. Risks associated with transfusion therapy, such as transfusion reactions, infection transmission, and iron overload, necessitate careful monitoring and management. Personalized treatment approaches that consider individual patient characteristics, such as the severity of anemia, stage of HIV infection, and presence of co-infections, are essential to optimize outcomes and minimize risks. Integrating blood transfusions with

existing ART regimens and other supportive therapies requires a coordinated, multidisciplinary approach to ensure comprehensive and effective care.¹¹

Mechanisms of Wound Healing

Wound healing is a complex, dynamic process that occurs in a series of well-orchestrated phases: hemostasis, inflammation, proliferation, and remodeling. Each phase plays a critical role in restoring tissue integrity and function following injury. In individuals with HIV, the wound healing process can be compromised due to factors such as impaired immune response, chronic inflammation, and nutritional deficiencies. The first phase of wound healing, hemostasis, begins immediately after tissue injury. The primary objective during this phase is to prevent excessive blood loss through clot formation. Upon injury, blood vessels constrict, and platelets adhere to the exposed collagen fibers in the damaged tissue. Activated platelets release various growth factors and signaling molecules, including platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF- β), which are crucial for initiating the healing process.¹² In individuals living with HIV, the hemostatic response can be impaired due to potential thrombocytopenia or platelet dysfunction, complicating the initial phase of healing. Blood transfusions can provide platelets and clotting factors, enhancing the hemostatic response and stabilizing the wound site. This stabilization is essential for the subsequent phases of healing, as a strong clot provides a scaffold for incoming cells and serves as a barrier to infection.¹³

Following hemostasis, the inflammatory phase begins, characterized by the recruitment of immune cells to the wound site. Neutrophils are typically the first responders, arriving within hours to clear debris, bacteria, and damaged tissue. They release reactive oxygen species (ROS) and proteolytic enzymes to aid in this process. As the inflammation progresses, monocytes migrate to the wound, differentiating into macrophages, which play a pivotal role in orchestrating the healing process.¹⁴ Macrophages are crucial for both pro-inflammatory and anti-inflammatory responses. They secrete a variety of cytokines, such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF- α), and IL-6, which are essential for further recruitment of immune cells and the transition to the proliferation phase. In HIV-positive individuals, the immune response may be dysregulated, leading to persistent inflammation and impaired healing. Blood transfusions can enhance immune function by replenishing circulating immune cells and modulating cytokine release, potentially reducing chronic inflammation and facilitating the healing process.¹⁵ The proliferation phase follows the inflammatory stage and is characterized by tissue formation, angiogenesis, and re-epithelialization. Fibroblasts, key cells in this phase, migrate to the wound site and proliferate to synthesize extracellular matrix components, including collagen, which provides structural support to the newly formed tissue. Collagen deposition is crucial for wound strength and integrity.¹⁶ Oxygen plays a vital role during the proliferation phase, as it is necessary for collagen

synthesis and cellular metabolism. Anemia, prevalent among individuals with HIV, compromises oxygen delivery to tissues, impairing cellular functions critical for healing. Blood transfusions can correct anemia and improve oxygenation, thereby enhancing the proliferation of fibroblasts and facilitating the synthesis of collagen and other extracellular matrix components.¹⁷ In parallel, angiogenesis, the formation of new blood vessels, occurs during this phase, driven by hypoxia-inducible factors (HIFs) and vascular endothelial growth factor (VEGF). Adequate blood flow is essential for delivering oxygen and nutrients to the healing tissue, further promoting cellular activities required for effective wound healing. By enhancing oxygen delivery and supporting angiogenesis, blood transfusions can significantly improve the wound healing process in HIV-positive individuals.

The final phase of wound healing, remodeling, can last for months to years after the initial injury. During this phase, the newly formed tissue undergoes maturation and reorganization to restore the skin's strength and elasticity. Collagen fibers are remodeled, and the extracellular matrix is restructured to enhance tissue integrity. This phase is essential for achieving optimal functional recovery and minimizing scarring.¹⁸ In HIV-positive individuals, the remodeling phase can be disrupted due to ongoing immune dysregulation and chronic inflammation, leading to poor-quality scar formation and increased risk of recurrent wounds. Blood transfusions may support the remodeling phase by providing essential growth factors and signaling molecules that facilitate tissue maturation and collagen remodeling. Additionally, by addressing anemia and enhancing oxygenation, transfusions can improve the overall healing environment, contributing to better long-term outcomes.¹⁹ Oxygen delivery is a critical component of effective wound healing, as adequate oxygenation is necessary for cellular metabolism, energy production, and the synthesis of vital extracellular matrix components. In individuals with HIV, the presence of anemia can significantly impair oxygen transport, leading to compromised tissue repair processes. Blood transfusions are a key therapeutic intervention that can restore hemoglobin levels and enhance oxygen delivery to tissues, thereby supporting the complex mechanisms involved in wound healing.²⁰

Importance of Oxygen in Wound Healing

Oxygen plays a multifaceted role in wound healing, influencing various cellular processes essential for tissue repair. The following are key aspects of how oxygen contributes to wound healing:

1. **Cellular Metabolism:** Oxygen is required for aerobic metabolism, which is the primary source of energy (ATP) for cells. Adequate ATP production is vital for the proliferation and migration of key cells involved in wound healing, such as fibroblasts and keratinocytes.²¹
2. **Collagen Synthesis:** Collagen, the most abundant protein in the extracellular matrix, provides structural support to wounds. Oxygen is a cofactor for

prolyl hydroxylase, an enzyme essential for collagen synthesis and stabilization. Insufficient oxygen levels can lead to impaired collagen production, resulting in weak and poorly organized tissue.²²

3. **Angiogenesis:** The formation of new blood vessels, or angiogenesis, is crucial during the proliferation phase of wound healing. Hypoxia-inducible factors (HIFs) stimulate the expression of vascular endothelial growth factor (VEGF), promoting angiogenesis. Sufficient oxygen levels are necessary to support this process, ensuring that new blood vessels can adequately supply oxygen and nutrients to the healing tissue.²³
4. **Immune Function:** Oxygen is essential for the functioning of immune cells. Neutrophils and macrophages utilize reactive oxygen species (ROS) to kill pathogens and clear debris at the wound site. Adequate oxygen delivery enhances the effectiveness of these immune responses, reducing the risk of infection and facilitating the transition to the healing phases.²⁴

Anemia and Impaired Oxygen Delivery

Anemia is a common complication in individuals living with HIV and can result from various factors, including chronic disease, opportunistic infections, and side effects of antiretroviral therapy (ART). This condition leads to a decreased concentration of hemoglobin in the blood, which in turn reduces the oxygen-carrying capacity. Consequently, tissues may become hypoxic, impairing cellular functions essential for wound healing. In HIV-positive individuals, the combination of anemia and immune dysfunction can create a challenging environment for wound healing. The presence of hypoxia can prolong the inflammatory phase, impair cellular migration and proliferation, and ultimately delay tissue repair. This situation increases the risk of chronic wounds, infection, and other complications, making effective management of anemia crucial for improving healing outcomes.²⁵

Role of Blood Transfusions

Blood transfusions serve as a valuable therapeutic option for addressing anemia and improving oxygen delivery in individuals living with HIV. By replenishing hemoglobin levels, transfusions can restore the oxygen-carrying capacity of the blood, facilitating improved oxygenation of tissues.

1. **Correction of Anemia:** Blood transfusions can quickly and effectively correct severe anemia, providing immediate relief from the symptoms associated with low hemoglobin levels. This correction can enhance the overall health and well-being of HIV-positive patients, contributing to improved energy levels and quality of life.
2. **Enhanced Tissue Oxygenation:** By increasing hemoglobin levels, blood transfusions significantly improve the delivery of oxygen to tissues. This enhancement supports the metabolic demands of cells involved in the wound healing process,

promoting efficient cellular activities necessary for tissue repair.

3. **Support for Cellular Functions:** Improved oxygenation facilitates cellular functions critical for wound healing, including fibroblast proliferation, collagen synthesis, and angiogenesis. These processes are essential for the transition from the inflammatory phase to the proliferation phase, allowing for effective tissue regeneration and repair.
4. **Improved Immune Responses:** Adequate oxygen levels also enhance the function of immune cells, supporting their ability to combat infection and clear debris at the wound site. This immune support is particularly important for HIV-positive individuals, who may have compromised immune responses.²⁶

Considerations and Risks

While blood transfusions can provide substantial benefits in improving oxygen delivery, they are not without risks. Potential complications, such as transfusion reactions, infection transmission, and iron overload, must be carefully considered. Additionally, the decision to administer blood transfusions should be guided by individual patient characteristics, including the severity of anemia, overall health status, and the presence of comorbid conditions. To optimize outcomes, healthcare providers should monitor patients closely during and after transfusion therapy. Implementing evidence-based transfusion protocols and ensuring patient education about the risks and benefits of transfusion therapy can enhance patient safety and improve overall care.²⁷ Wound healing is a highly coordinated process that relies not only on cellular activities but also on the immune system's response to injury. In individuals living with HIV, where immune dysfunction and chronic inflammation are prevalent, the processes of wound healing can be significantly impaired. Blood transfusions may play a pivotal role in modulating immune responses and reducing inflammation, thereby enhancing the overall healing process.²⁸ The immune system is essential for effective wound healing, as it orchestrates the initial inflammatory response, clears pathogens, and facilitates tissue repair. Neutrophils are among the first responders to a wound, arriving shortly after injury to phagocytose bacteria and debris. They release reactive oxygen species (ROS) and proteolytic enzymes that help to clear the wound area. Following neutrophils, monocytes migrate to the wound site, differentiating into macrophages, which play a critical role in orchestrating the healing process. Macrophages secrete various cytokines (such as IL-1, TNF- α , and IL-6) and growth factors (like VEGF and PDGF) that recruit additional immune cells, promote angiogenesis, and stimulate fibroblast proliferation and collagen synthesis. This signaling cascade is vital for progressing through the healing phases. T cells, particularly CD4⁺ T helper cells, are involved in regulating immune responses and can influence the healing process through cytokine production. In HIV-positive individuals, the depletion of CD4⁺ T cells can lead to an inadequate immune response, impairing wound healing.²⁹⁻³⁰

In individuals with HIV, chronic inflammation is a common feature resulting from persistent immune activation due to ongoing viral replication and the effects of ART. Chronic inflammation can prolong the inflammatory phase of wound healing, delaying the transition to the proliferation phase. Pro-inflammatory cytokines can contribute to excessive tissue damage and prevent effective healing, increasing the risk of chronic wounds. Persistent inflammation can also impair the remodeling phase of wound healing, leading to poor-quality scar formation and decreased tissue integrity. This issue can further predispose individuals to recurrent wounds and complications. A dysregulated immune response increases susceptibility to infections, which can significantly hinder the healing process and further exacerbate chronic inflammation.³¹⁻³² Blood transfusions can exert several beneficial effects on immune modulation and inflammation reduction in HIV-positive individuals, potentially addressing some of the challenges associated with chronic inflammation and impaired wound healing. Blood transfusions provide not only red blood cells but also plasma, platelets, and white blood cells. This replenishment can help restore a more balanced immune environment, enhancing the overall immune response at the wound site. Research has indicated that blood transfusions can reduce the levels of pro-inflammatory cytokines, such as IL-6 and TNF- α , which are often elevated in HIV-positive individuals. This reduction can help mitigate chronic inflammation, allowing for a more favorable environment for healing. Adequate hemoglobin levels resulting from blood transfusions can enhance macrophage function, allowing these cells to more effectively clear debris and pathogens. This improvement is crucial for the transition from the inflammatory phase to the proliferation phase of wound healing. Blood transfusions may stimulate anti-inflammatory pathways, promoting the secretion of anti-inflammatory cytokines such as IL-10. This shift can help resolve inflammation more quickly, facilitating the healing process.³³⁻³⁴ Emerging clinical evidence suggests that blood transfusions can positively influence immune function and inflammatory responses in HIV-positive individuals. Studies have reported improvements in wound healing outcomes, with patients experiencing faster wound closure and reduced infection rates following transfusion therapy. These findings highlight the potential of blood transfusions not only to correct anemia but also to modulate immune responses and reduce chronic inflammation.³⁵

Considerations and Risks

While blood transfusions can provide significant benefits for immune modulation and inflammation reduction, they also carry inherent risks. Potential complications, including transfusion reactions, infections, and iron overload, must be carefully managed. Monitoring patients during and after transfusion therapy is essential to mitigate risks and optimize outcomes. Integrating blood transfusions into a comprehensive care approach for HIV-positive individuals is crucial for maximizing their benefits. Collaboration among healthcare providers, including infectious disease specialists, hematologists, and wound care experts, is essential for developing

personalized treatment plans that address the unique needs of each patient.³⁶ While blood transfusions can provide significant benefits for individuals living with HIV, particularly in enhancing wound healing through improved oxygen delivery and immune modulation, several challenges and considerations must be taken into account. These include the risks associated with transfusion therapy, the need for individualized patient assessment, and the integration of transfusions into a broader treatment framework. Although blood transfusions can be life-saving and improve healing outcomes, they are not without risks. Allergic reactions, febrile non-hemolytic transfusion reactions, and acute hemolytic reactions can occur following blood transfusions. These reactions may range from mild to severe and require immediate medical attention. Although the risk of transmitting infections (such as HIV, hepatitis B, and hepatitis C) through transfusions has been significantly reduced due to rigorous screening and testing protocols, there remains a small risk of transmission of other pathogens, such as bacterial infections or emerging infectious agents. Repeated blood transfusions can lead to iron overload, which can damage organs and tissues over time. This concern is particularly relevant in patients requiring multiple transfusions for chronic anemia, necessitating careful monitoring of iron levels and potentially using chelation therapy.³⁸

The decision to administer blood transfusions should be based on a thorough assessment of each patient's unique clinical situation. The level of anemia and its impact on the patient's overall health and quality of life should be assessed. Blood transfusions may be more urgently required in cases of severe anemia with significant symptomatic effects, while milder cases may be managed with other interventions, such as iron supplementation or erythropoietin-stimulating agents. The presence of comorbid conditions, such as cardiovascular disease or diabetes, can influence the decision to transfuse. Patients with certain conditions may be at higher risk for complications associated with transfusion therapy. HIV-positive individuals may experience immune dysregulation, affecting their ability to tolerate transfusions. Healthcare providers should consider each patient's immunological status when determining the appropriateness of transfusion therapy.³⁹ When considering blood transfusions for HIV-positive individuals, it is crucial to integrate this intervention with ongoing antiretroviral therapy (ART). Effective ART is essential for controlling viral replication and preserving immune function. Coordinating transfusion therapy with ART can enhance overall treatment outcomes and minimize potential interactions or complications. Regular monitoring of viral load and CD4 counts is necessary to assess the effectiveness of ART and the patient's immune status. Transfusion therapy should be coordinated with these assessments to optimize patient care. While no direct interactions between blood transfusions and ART have been established, providers should remain vigilant regarding any potential effects of transfusion therapy on the immune response or the efficacy of ART.⁴⁰

Discussing the risks associated with transfusion therapy allows patients to understand the potential for transfusion reactions and infection transmission. Educating patients on how transfusions can enhance oxygen delivery, support immune function, and promote wound healing can help them appreciate the importance of this intervention. Ensuring that patients provide informed consent before transfusion therapy is crucial. Patients should have the opportunity to ask questions and discuss their concerns with their healthcare providers. The integration of blood transfusions with antiretroviral therapy (ART) and comprehensive care is essential for optimizing the health outcomes of individuals living with HIV, particularly in the context of enhancing wound healing. A coordinated approach that addresses the multifaceted needs of patients can improve not only their immune function and wound healing but also their overall quality of life. This section explores the importance of integrating blood transfusions with ART and other aspects of comprehensive care.⁴¹

Effective ART reduces the viral load in the body, leading to improved immune function and a lower risk of opportunistic infections. This enhancement allows for a more robust response to blood transfusions and better wound healing outcomes. ART helps restore CD4+ T cell counts, which are vital for coordinating immune responses. Improved CD4 counts can enhance the efficacy of blood transfusions by promoting better immune modulation and inflammatory control at the wound site. Nutrition plays a crucial role in wound healing and immune function. Assessing and addressing nutritional deficiencies can enhance the effectiveness of both ART and blood transfusions. Nutritional counseling and supplementation may be necessary for patients with malnutrition, which is common in those living with HIV. Many individuals with HIV may have comorbid conditions, such as diabetes, cardiovascular disease, or mental health disorders. Comprehensive care should involve the management of these conditions to optimize overall health and improve responses to transfusions and ART. Addressing the psychological and social factors affecting patients is essential. Mental health support, access to social services, and counseling can improve treatment adherence and overall well-being.⁴²

Encouraging open discussions about treatment options, including the benefits and risks of blood transfusions, empowers patients to participate actively in their care. This involvement enhances their understanding of the importance of ART and transfusions in managing their health. Providing education on the relationship between HIV, wound healing, and the role of blood transfusions can improve adherence to treatment. Patients should be informed about the importance of maintaining a healthy lifestyle, including proper nutrition, exercise, and adherence to ART. Healthcare providers should conduct regular assessments of hemoglobin levels, immune function (CD4 counts), and viral load to evaluate the effectiveness of ART and transfusion therapy. This monitoring helps guide treatment decisions and adjust care as needed. Regular follow-up for wound assessment and care is crucial to identify any signs of infection, delayed healing, or other complications early. Prompt

intervention can prevent further issues and enhance healing outcomes. Based on the results of monitoring, healthcare providers may need to adjust ART regimens, transfusion protocols, or other aspects of care to optimize patient outcomes.⁴³

Conclusion

Blood transfusions represent a crucial intervention for individuals living with HIV, particularly in enhancing wound healing through improved oxygen delivery, immune modulation, and inflammation reduction. This comprehensive review highlights the significant benefits of transfusion therapy, especially for those experiencing anemia and other complications related to HIV. By restoring hemoglobin levels, blood transfusions not only enhance tissue oxygenation but also support the complex cellular processes essential for effective wound healing. The integration of blood transfusions with antiretroviral therapy (ART) and comprehensive care is vital for optimizing health outcomes. A coordinated approach that involves various healthcare providers—such as infectious disease specialists, hematologists, wound care experts, nutritionists, and mental health professionals—ensures that patients receive holistic and individualized care. By addressing the multifaceted needs of patients, healthcare teams can improve treatment adherence, manage comorbid conditions, and foster better overall health and quality of life.

References

- Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 37-50
- Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*, 2024; 2(1): 33-45
- Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*, 2024; 2(1):10-22
- Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. *Medicine*. 2024;103(2): e36937. <https://doi.org/10.1097/MD.00000000000036937> PMID:38215133 PMCID:PMC10783375
- Volberding P. The impact of anemia on quality of life in human immunodeficiency virus-infected patients. *The Journal of infectious diseases*. 2002;185(Supplement_2): S110-114. <https://doi.org/10.1086/340198> PMID:12001031
- Montoro M, Cucala M, Lanás Á, Villanueva C, Hervás AJ, Alcedo J, Gisbert JP, Aisa ÁP, Bujanda L, Calvet X, Mearin F. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts. *Frontiers in Medicine*. 2022; 9:903739. <https://doi.org/10.3389/fmed.2022.903739> PMID:36186804 PMCID:PMC9519983
- Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):11-24. <https://doi.org/10.22270/ijmspr.v10i2.95>
- Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences*. 2023;3(2):7-14. <https://doi.org/10.22270/ajdhs.v3i2.39>
- Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. *Blood, The Journal of the American Society of Hematology*. 2019;133(17):1854-1864. <https://doi.org/10.1182/blood-2018-11-833996> PMID:30808637
- Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2024;11(2):9-19.
- Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: http://www.journalijiar.com*;12(01).
- Heron SE, Elahi S. HIV infection and compromised mucosal immunity: oral manifestations and systemic inflammation. *Frontiers in immunology*. 2017; 8:241. <https://doi.org/10.3389/fimmu.2017.00241> PMID:28326084 PMCID:PMC5339276
- Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 17-41
- Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2024;11(2):30-40.
- Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*, 2024; 2(1): 51-64
- Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*, 2024; 2(1): 1-16
- Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. *Transfusion medicine reviews*. 2012;26(2):164-180. <https://doi.org/10.1016/j.tmr.2011.07.006> PMID:21872426 PMCID:PMC3668661
- Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*, 2024; 2(1): 14-32
- Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*, 2024; 2(1): 24-36
- Cunningham-Rundles S, McNeeley DF, Moon A. Mechanisms of nutrient modulation of the immune response. *Journal of Allergy and Clinical immunology*. 2005;115(6):1119-1128. <https://doi.org/10.1016/j.jaci.2005.04.036> PMID:15940121
- Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2024;11(2):41-51. <https://doi.org/10.22270/ijmspr.v10i2.102>
- Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*, 2024; 2(3): 14-26
- Obeagu EI, Elamin EAI, Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. *Elite Journal of Haematology*, 2024; 2(3): 111-117
- Lotfi R, Kaltenmeier C, Lotze MT, Bergmann C. Until death do us part: necrosis and oxidation promote the tumor microenvironment. *Transfusion Medicine and Hemotherapy*. 2016 Mar 8;43(2):120-32. <https://doi.org/10.1159/000444941> PMID:27226794 PMCID:PMC4872058
- Cunha PP, Minogue E, Krause LC, Hess RM, Bargiela D, Wadsworth BJ, Barbieri L, Brombach C, Foskolou IP, Bogeski I, Velica P. Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy. *Elife*. 2023;12:e84280. <https://doi.org/10.7554/eLife.84280> PMID:37166103 PMCID:PMC10229120
- Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A

- Review. *Elite Journal of Nursing and Health Science*, 2024; 2(3): 38-58
27. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. *Elite Journal of Health Science*, 2024; 2(3): 23-35
28. Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. *Viruses*. 2019;11(3):200. <https://doi.org/10.3390/v11030200> PMID:30818749 PMCID:PMC6466530
29. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology*, 2024; 2(2): 43-59
30. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology*, 2024; 2(3): 42-57
31. Balderson BH, Grothaus L, Harrison RG, McCoy K, Mahoney C, Catz S. Chronic illness burden and quality of life in an aging HIV population. *AIDS care*. 2013;25(4):451-458. <https://doi.org/10.1080/09540121.2012.712669> PMID:22894702 PMCID:PMC3535557
32. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*, 2024; 2(2): 5-15
33. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*, 2024; 2(3): 59-72
34. Chakraborty R, Cannella L, Cottone F, Efficace F. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. *The Lancet Haematology*. 2020;7(12):e892-901. [https://doi.org/10.1016/S2352-3026\(20\)30292-1](https://doi.org/10.1016/S2352-3026(20)30292-1) PMID:33242446
35. Hébert PC, Fergusson D, Blajchman MA, Wells GA, Kmetc A, Coyle D, Heddle N, Germain M, Goldman M, Toye B, Schweitzer I. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. *Jama*. 2003;289(15):1941-1949. <https://doi.org/10.1001/jama.289.15.1941> PMID:12697796
36. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. *Blood, The Journal of the American Society of Hematology*. 2009;113(15):3406-3417. <https://doi.org/10.1182/blood-2008-10-167643> PMID:19188662
37. Kaur P, Basu S. Transfusion-transmitted infections: existing and emerging pathogens. *Journal of postgraduate medicine*. 2005;51(2):146-151.
38. Wiersum-Osselton JC, Whitaker B, Grey S, Land K, Perez G, Rajbhandary S, Andrzejewski C, Bolton-Maggs P, Lucero H, Renaudier P, Robillard P. Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study. *The Lancet Haematology*. 2019;6(7):e350-358. [https://doi.org/10.1016/S2352-3026\(19\)30080-8](https://doi.org/10.1016/S2352-3026(19)30080-8) PMID:31080132
39. Smit-Sibinga C, Pitman JP. Transmission of HIV through blood-how to bridge the knowledge gap. In *HIV and AIDS-Updates on biology, immunology, epidemiology and treatment strategies 2011*: 583-618. InTech, Rijeka, Croatia. <https://doi.org/10.5772/19618> PMCID:PMC3157305
40. Slonim AD, Bish EK, Xie RS. Red blood cell transfusion safety: probabilistic risk assessment and cost/benefits of risk reduction strategies. *Annals of Operations Research*. 2014; 221:377-406. <https://doi.org/10.1007/s10479-011-0925-0>
41. Steffen KM, Spinella PC, Holdsworth LM, Ford MA, Lee GM, Asch SM, Proctor EK, Doctor A. Factors influencing implementation of blood transfusion recommendations in pediatric critical care units. *Frontiers in Pediatrics*. 2021; 9:800461. <https://doi.org/10.3389/fped.2021.800461> PMID:34976903 PMCID:PMC8718763
42. Barro L, Drew VJ, Poda GG, Tagny CT, El-Ekiaby M, Owusu-Ofori S, Burnouf T. Blood transfusion in sub-Saharan Africa: understanding the missing gap and responding to present and future challenges. *Vox Sanguinis*. 2018;113(8):726-736. <https://doi.org/10.1111/vox.12705> PMID:30221365
43. Ako S, Njunda LA, Akum EA, Benjamin PT, Assob J. Hematological related disorders and transfusion of HIV patients on highly active antiretroviral therapy (HAART) in the South West Region of Cameroon: hematological monitory parameters for HIV follow-up. *J HIV Retrovirus*. 2018;4(1):5